# Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
Canonical URL: https://biopharmsignal.com/news/TARA/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-and-eha
Ticker: TARA
Company: Protara Therapeutics
Source: Protara Therapeutics
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.protaratx.com
## Summary

NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat

## Article Body
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat
## Recent Company News
- 2026-06-25 13:46 EST — [Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA](https://biopharmsignal.com/news/TARA/protara-therapeutics-to-present-at-the-td-cowen-7th-annual-oncology-innovation-summit-insights-for-asco-and-eha) — Source: Protara Therapeutics
- 2026-06-25 13:46 EST — [Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026](https://biopharmsignal.com/news/TARA/protara-therapeutics-to-host-virtual-investor-webinar-to-discuss-tara-002-for-lymphatic-malformations-on-tuesday-may-19-2026) — Source: Protara Therapeutics
- 2026-06-25 13:46 EST — [Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC](https://biopharmsignal.com/news/TARA/protara-therapeutics-announces-positive-updated-12-month-data-demonstrating-durable-responses-in-the-fully-enrolled-bcg-naive-cohort-of-the-ongoing-phase-2-advanced-2-trial-of-tara-002-in-nmibc) — Source: Protara Therapeutics
- 2026-06-25 13:46 EST — [Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update](https://biopharmsignal.com/news/TARA/protara-therapeutics-announces-first-quarter-2026-financial-results-and-provides-a-business-update) — Source: Protara Therapeutics
- 2026-06-25 13:46 EST — [Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations](https://biopharmsignal.com/news/TARA/protara-therapeutics-receives-both-fda-breakthrough-therapy-and-fast-track-designations-for-tara-002-in-pediatric-patients-with-lymphatic-malformations) — Source: Protara Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)